AstraZeneca Annual Report and Financial Statements Form 20-F Information 2004 95 19 Provisions for liabilities and charges Environmental, litigation Employee and other Deferred benefits Pensions provisions taxation Total $m $m $m $m $m At 1 January 2003 139 234 190 1,210 1,773 Profit and loss account 50 72 48 232 402 Net amounts paid or becoming current 57 57 65 179 Other movements, including exchange 58 34 30 148 270 At 31 December 2003 190 283 203 1,590 2,266 Profit and loss account 17 56 2 46 25 Net amounts paid or becoming current 52 64 71 187 Other movements, including exchange 22 29 15 37 103 At 31 December 2004 177 304 145 1,581 2,207 Employee benefit provisions comprise post-retirement and other employee benefit provisions.
Further details of environmental provisions are given in Note 30.
No provision has been released or applied for any purpose other than that for which it was established.
20 Reconciliation of movements in shareholders funds 2004 2003 2002 $m $m $m Shareholders funds at beginning of year 13,178 11,172 9,586 Net profit for the financial year 3,813 3,036 2,836 Dividends 1,555 1,350 1,206 Profit retained for the financial year 2,258 1,686 1,630 Issues of AstraZeneca PLC Ordinary Shares 102 47 36 Re-purchase of AstraZeneca PLC Ordinary Shares 2,212 1,154 1,190 Foreign exchange adjustments on consolidation, net of tax 1,092 1,427 1,106 Translation differences on foreign currency borrowings 6 Tax on translation differences on foreign currency borrowings 2 Net addition to shareholders funds 1,240 2,006 1,586 Shareholders funds at end of year 14,418 13,178 11,172 Included in foreign exchange adjustments on consolidation, is a tax credit in 2004 of $357m in respect of foreign exchange loss deductions arising in 2000 see Note 5.
